Zinepra 5 Tablet SR is a sustained-release formulation combining Propranolol 40mg and Flunarizine 5mg, indicated for the prophylaxis and management of migraine headaches and certain cardiovascular conditions. Propranolol, a non-selective beta-adrenergic blocker, exerts its therapeutic effects by reducing heart rate, myocardial contractility, and blood pressure, thereby decreasing cardiac workload and oxygen demand. It is commonly utilized in the prevention of angina pectoris, hypertension, and arrhythmias. Flunarizine, a calcium channel blocker with antihistaminic properties, acts by inhibiting the influx of calcium ions into vascular smooth muscle and neuronal cells, contributing to cerebral vasodilation and stabilization of neuronal excitability. This dual-action combination is particularly effective in reducing the frequency and severity of migraine attacks by modulating vascular tone and neuronal hyperexcitability. Zinepra 5 Tablet SR’s sustained-release mechanism ensures a gradual and prolonged drug release, enhancing patient compliance and maintaining steady plasma concentrations. It is contraindicated in patients with asthma, severe bradycardia, or hypersensitivity to either component. Common adverse effects may include fatigue, dizziness, gastrointestinal disturbances, and peripheral edema. Dosage should be individualized based on clinical response and tolerability, with careful monitoring in patients with comorbid conditions.